Should postoperative radiation therapy be given for a patient with T2 hormone‑receptor‑positive breast cancer who has a single positive axillary node with extranodal extension after a modified radical mastectomy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Should Radiation Be Considered in Extranodal Extension in pT2 Single Node Hormone Positive Breast Cancer After MRM?

Yes, postmastectomy radiation therapy (PMRT) should be strongly considered for this patient with T2 hormone-receptor-positive breast cancer with a single positive node showing extranodal extension (ENE), as ENE represents a high-risk feature that significantly increases distant metastasis risk and warrants comprehensive locoregional radiation including chest wall and regional nodes. 1

Risk Stratification and ENE Significance

The presence of extranodal extension fundamentally changes the risk profile of this patient:

  • ENE is an independent adverse prognostic factor that significantly increases the risk of distant metastases (hazard ratio 2.71,95% CI 1.316-5.581, p=0.007), with 3-year and 5-year metastasis-free survival rates of 78% and 66% respectively in ENE-positive patients versus 90% and 87% in ENE-negative patients. 2

  • ENE correlates with decreased overall survival (p=0.05) independent of the number of positive nodes, though the number of positive nodes remains the stronger predictor (p=0.003). 3

  • For T1-T2 N1 patients specifically, ENE-positive disease with high histological grade showed statistically significant improvement in both locoregional failure-free survival (p=0.026) and overall survival (p=0.007) with PMRT, while low-risk patients without ENE showed no benefit. 4

Current Guideline Recommendations

The most recent ESMO 2024 guidelines provide clear direction:

  • PMRT should be considered in patients with intermediate-risk features including 1-3 positive axillary lymph nodes, particularly when combined with other risk factors like lymphovascular invasion. 1

  • Comprehensive locoregional RT encompassing chest wall and all regional lymph nodes improves outcomes, especially for patients with axillary node involvement, with significant reduction in breast cancer mortality (rate ratio 0.87,95% CI 0.80-0.94, p=0.0010). 1

  • When PMRT is used for patients with positive axillary lymph nodes, treatment should generally be administered to both the internal mammary nodes and supraclavicular-axillary apical nodes in addition to the chest wall. 5

The ENE Paradox: Local vs Systemic Risk

An important nuance exists regarding ENE:

  • ENE does NOT significantly increase axillary recurrence risk - studies show extremely low axillary recurrence rates (0-2%) even in ENE-positive patients, whether or not they received axillary radiation. 6, 3

  • However, ENE is strongly associated with systemic failure, suggesting it represents aggressive tumor biology rather than simply inadequate local control. 2

  • Despite this, modern locoregional RT reduces distant recurrence, not just local recurrence, likely through elimination of micrometastatic disease in regional nodes. 1

Treatment Algorithm for This Patient

Given T2 tumor + single positive node + ENE + hormone receptor-positive status:

  1. Recommend PMRT with comprehensive regional nodal irradiation including:

    • Chest wall
    • Supraclavicular-axillary apical nodes (levels 1-4)
    • Internal mammary nodes 5, 1

  2. Modern hypofractionated regimens are appropriate: 15-16 fractions of 2.50-2.67 Gy or even ultra-hypofractionation (26 Gy in 5 fractions) for chest wall, though data for ultra-hypofractionation with comprehensive nodal RT are still maturing. 1

  3. Coordinate timing with systemic therapy: The decision should be made in multidisciplinary fashion early in treatment course, ideally before or soon after initiation of systemic therapy. 5

Caveats and Common Pitfalls

  • Do not use ENE as sole indication for axillary boost radiation - the benefit of PMRT in ENE-positive patients comes from comprehensive locoregional treatment, not isolated axillary irradiation. 6, 3

  • Genomic testing may refine decisions in the future: Emerging data suggest that patients with 1-3 positive nodes and recurrence score ≤25 may have excellent outcomes without PMRT (5-year OS 98.1% vs 97.5%, p=0.093), though this study did not specifically analyze ENE-positive subsets. 7

  • Hormone receptor-positive status does not negate radiation benefit - while endocrine therapy is critical, T3-T4 N1 hormone receptor-positive patients with ENE showed improved outcomes with PMRT. 4

  • Adequate axillary dissection is assumed - these recommendations presume complete axillary lymph node dissection has been performed; if only sentinel node biopsy was done, regional nodal irradiation becomes even more important. 5, 1

References

3
Research

Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995

Related Questions

Should postoperative radiation be given for a patient with T2, N2a, hormone-receptor-positive breast cancer with extra-nodal extension after a modified radical mastectomy?
What is the preferred neoadjuvant regimen for a woman with newly diagnosed stage II–III HER2‑positive breast cancer according to the TRAIN‑2 trial?
What adjuvant chemotherapy regimen is appropriate for a 70‑year‑old woman with a T2 hormone‑receptor‑positive, HER2‑negative breast cancer, one positive lymph node with extranodal extension after a modified radical mastectomy, and how should it be tailored to her age and tolerance?
What is the expected survival for a patient with metastatic breast cancer to brain, bone, and liver who has daily falls, urinary incontinence, severe headaches, and excessive sleepiness?
What is the recommended approach to monitor treatment response in a patient with hormone‑receptor‑positive, HER2‑negative breast cancer?
What QTc interval values are considered safe to initiate antipsychotic therapy in men and women?
In a 56-year-old female with atrial fibrillation, hypertension, and a thyroid nodule scheduled for subtotal thyroidectomy in three weeks, who is on chronic warfarin with an INR of 2.3 and has no history of coronary artery disease, peripheral vascular disease, or stroke, what perioperative anticoagulation strategy should be recommended?
What is the best oral antibiotic for an 85-year-old male with a urinary tract infection, no drug allergies, and a serum creatinine of 0.89 mg/dL (estimated GFR ≈ 84 mL/min)?
How do I calculate the oral rehydration solution volume needed to replace stool losses in a child with diarrhea, including the appropriate dose per kilogram and replacement timeframe?
What are the types of inguinal hernia?
Can fluoxetine be used when the corrected QT interval is 492 ms?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question